Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid
Zhuo-Yue Li,1,2 Yi-Fan Yin,1,2 Yang Guo,1,2 Hui Li,1,2 Mei-Qi Xu,1,2 Man Liu,1,2 Jing-Ru Wang,1,2 Zhen-Han Feng,1,2 Xiao-Chuan Duan,1,2 Shuang Zhang,1,2 Shuai-Qiang Zhang,1,2 Guang-Xue Wang,2 Ai Liao,2 Shu-Min Wang,3 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Deliv...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5d8d06cbef1d41e084540efd3c785fdf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5d8d06cbef1d41e084540efd3c785fdf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5d8d06cbef1d41e084540efd3c785fdf2021-12-02T05:21:47ZEnhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid1178-2013https://doaj.org/article/5d8d06cbef1d41e084540efd3c785fdf2020-03-01T00:00:00Zhttps://www.dovepress.com/enhancing-anti-tumor-activity-of-sorafenib-mesoporous-silica-nanomatri-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Zhuo-Yue Li,1,2 Yi-Fan Yin,1,2 Yang Guo,1,2 Hui Li,1,2 Mei-Qi Xu,1,2 Man Liu,1,2 Jing-Ru Wang,1,2 Zhen-Han Feng,1,2 Xiao-Chuan Duan,1,2 Shuang Zhang,1,2 Shuai-Qiang Zhang,1,2 Guang-Xue Wang,2 Ai Liao,2 Shu-Min Wang,3 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 3Department of Ultrasound, Peking University Third Hospital, Peking University, Beijing 100191, People’s Republic of ChinaCorrespondence: Xuan ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaTel/Fax +86-10-82805765Email xuanzhang@bjmu.edu.cnShu-Min WangDepartment of Ultrasound, Peking University Third Hospital, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaEmail shuminwang2014@163.comIntroduction: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti–inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN.Methods: Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively.Results: The results indicated that FFA could markedly decrease cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The enhanced anti-tumor activity of MSNM@SFN+FFA compared with that of MSNM@SFN was confirmed in the 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model in vivo, respectively.Discussion: MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) developed in this study is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs.Keywords: sorafenib mesoporous silica nanomatrix, MSNM@SFN, flufenamic acid, FFA, PGE2, AKR1C1, AKR1C3, 4T1/luc, HepG2Li ZYYin YFGuo YLi HXu MQLiu MWang JRFeng ZHDuan XCZhang SZhang SQWang GXLiao AWang SMZhang XDove Medical Pressarticlesorafenib mesoporous silica nanomatrix (msnm@sfn)flufenamic acid (ffa)pge2akr1c1akr1c34t1/luchepg2Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 1809-1821 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
sorafenib mesoporous silica nanomatrix (msnm@sfn) flufenamic acid (ffa) pge2 akr1c1 akr1c3 4t1/luc hepg2 Medicine (General) R5-920 |
| spellingShingle |
sorafenib mesoporous silica nanomatrix (msnm@sfn) flufenamic acid (ffa) pge2 akr1c1 akr1c3 4t1/luc hepg2 Medicine (General) R5-920 Li ZY Yin YF Guo Y Li H Xu MQ Liu M Wang JR Feng ZH Duan XC Zhang S Zhang SQ Wang GX Liao A Wang SM Zhang X Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| description |
Zhuo-Yue Li,1,2 Yi-Fan Yin,1,2 Yang Guo,1,2 Hui Li,1,2 Mei-Qi Xu,1,2 Man Liu,1,2 Jing-Ru Wang,1,2 Zhen-Han Feng,1,2 Xiao-Chuan Duan,1,2 Shuang Zhang,1,2 Shuai-Qiang Zhang,1,2 Guang-Xue Wang,2 Ai Liao,2 Shu-Min Wang,3 Xuan Zhang1,2 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, People’s Republic of China; 3Department of Ultrasound, Peking University Third Hospital, Peking University, Beijing 100191, People’s Republic of ChinaCorrespondence: Xuan ZhangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaTel/Fax +86-10-82805765Email xuanzhang@bjmu.edu.cnShu-Min WangDepartment of Ultrasound, Peking University Third Hospital, Peking University, Xueyuan Road 38, Beijing 100191, People’s Republic of ChinaEmail shuminwang2014@163.comIntroduction: Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti–inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN.Methods: Metastatic breast tumor 4T1/luc cells and hepatocellular carcinoma HepG2 cells were selected as cell models. The effects of FFA in vitro on cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in 4T1/luc and HepG2 cells were investigated. The in vivo anti-tumor activity of MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) was evaluated in a 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model, respectively.Results: The results indicated that FFA could markedly decrease cell migration, PGE2 secretion, and AKR1C1 and AKR1C3 levels in both 4T1/luc and HepG2 cells. The enhanced anti-tumor activity of MSNM@SFN+FFA compared with that of MSNM@SFN was confirmed in the 4T1/luc metastatic tumor model, HepG2 tumor-bearing nude mice model, and HepG2 orthotopic tumor-bearing nude mice model in vivo, respectively.Discussion: MSNM@SFN co-administrating with FFA (MSNM@SFN+FFA) developed in this study is an alternative strategy for improving the therapeutic efficacy of MSNM@SFN via co-administration with NSAIDs.Keywords: sorafenib mesoporous silica nanomatrix, MSNM@SFN, flufenamic acid, FFA, PGE2, AKR1C1, AKR1C3, 4T1/luc, HepG2 |
| format |
article |
| author |
Li ZY Yin YF Guo Y Li H Xu MQ Liu M Wang JR Feng ZH Duan XC Zhang S Zhang SQ Wang GX Liao A Wang SM Zhang X |
| author_facet |
Li ZY Yin YF Guo Y Li H Xu MQ Liu M Wang JR Feng ZH Duan XC Zhang S Zhang SQ Wang GX Liao A Wang SM Zhang X |
| author_sort |
Li ZY |
| title |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| title_short |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| title_full |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| title_fullStr |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| title_full_unstemmed |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid |
| title_sort |
enhancing anti-tumor activity of sorafenib mesoporous silica nanomatrix in metastatic breast tumor and hepatocellular carcinoma via the co-administration with flufenamic acid |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/5d8d06cbef1d41e084540efd3c785fdf |
| work_keys_str_mv |
AT lizy enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT yinyf enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT guoy enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT lih enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT xumq enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT lium enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT wangjr enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT fengzh enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT duanxc enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT zhangs enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT zhangsq enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT wanggx enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT liaoa enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT wangsm enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid AT zhangx enhancingantitumoractivityofsorafenibmesoporoussilicananomatrixinmetastaticbreasttumorandhepatocellularcarcinomaviathecoadministrationwithflufenamicacid |
| _version_ |
1718400412928704512 |